Brent is passionate about investing in cutting-edge medical technologies, diagnostics, and therapeutic treatments. Since joining Canaan in 1999, Brent has led successful investments in novel medical companies such as DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), Durata Therapeutics (DRTX), Elevation Pharmaceuticals (acquired by DNPUF); Spinifex (acquired by NVS), Semnur (acquired by SRNE).
Brent serves on the boards of Abyrx, a developer and manufacturer of therapeutic devices for use during surgical procedures; EndoGastric Solutions, the leading company offering medical devices for treatment of reflux disease; Grey Wolf Therapeutics, which is developing a novel cancer drug; Iterum Therapeutics, a developer of a broad-spectrum antibiotic to treat serious infections; Pathios Therapeutics is developing a novel drug to target cell surface receptors; Relievant MedSystems, a maker of minimally invasive devices to relieve chronic back pain; and Unchained Labs, a life science tools company.
Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. He also has several surgical instrument patents to his credit.
Education, Personal, and Fellowship
Brent earned an MBA from the Tuck School of Business at Dartmouth College and a BS and MS in mechanical engineering from the University of Dayton. An avid runner an skier, Brent can also be found tinkering on home carpentry projects when time permits.
Brent is a member of Class 5 and performed his fellowship at Canaan Partners under the mentorship of Harry Rein. He was later a mentor to John Pacifico (Class 12) and to Gil Canaani (Class 17).